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OBJECTIVES: The purpose of this study was to assess the reliability of the Brazilian version of the Functional
Assessment of Cancer Therapy-Lung (FACT-L) with the FACT-Lung Symptom Index (FLSI) questionnaire.
INTRODUCTION: The assessment of quality of life in patients with lung cancer has become an important evaluative
endpoint in current clinical trials. For lung cancer patients, one of the most common quality of life tools available is
the FACT-L. Despite the amount of data available regarding this questionnaire, there are no data on its performance
in Brazilian lung cancer patients.
METHODS: The FACT-L with the FLSI questionnaire was prospectively administered to 30 consecutive, stable, lung
cancer outpatients at baseline and at 2 weeks.
RESULTS: The intraclass correlation coefficient between test and retest for the FACT-L ranged from0.79 to 0.96 and for the
FLSI was 0.87. There was no correlation between these questionnaire dimensions and clinical or functional parameters.
CONCLUSIONS: The Brazilian version of the FACT-L with FLSI questionnaire is reliable and is quick and simple to
apply. This instrument can now be used to properly evaluate the quality of life of Brazilian lung cancer patients.
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INTRODUCTION
Lung cancer has become a disease of great global impact
and remains the leading cause of death from cancer in the
world.1 As smoking and environmental pollution cannot be
controlled in the short term, the incidence of lung cancer
continues to increase, especially in females.2,3 In Brazil, the
estimate for 2010 is approximately 18 new cases per 100 000
men and 10 per 100 000 women, corresponding to 17 800
and 9 930 new cases of lung cancer among men and women
respectively.4
Advances in lung cancer therapy have been improving
survival rates, although the prognosis remains poor. The 5-
year survival rate is around 15% in developed countries1
and 10% in Brazil.4 Therefore, the impact of both disease
and treatment on the health and psychosocial functioning of
these patients should be considered.5 In this context, quality
of life assessment and the analysis of the main symptoms
that lead to functional capacity limitation have become
issues of utmost importance in the evaluation of lung cancer
patients. However, in Brazil, there are few studies that
evaluate this aspect of the disease, mainly because of the
lack of specific tools adapted to and reproducible for the
Brazilian Portuguese language.
Several instruments are currently used to evaluate the
quality of life in patients with lung cancer. The Functional
Assessment of Cancer Therapy-Lung (FACT-L) was gener-
ated by the Functional Assessment of Chronic Illness Therapy
(FACIT) group. It is a specific, multidimensional question-
naire widely used in clinical studies.6-9 Moreover, the FACT-
Lung Symptom Index (FLSI), which is a brief measure
involving five common symptoms in lung cancer patients,
can be applied in combination with the FACT-L or alone.
Although the FACT-L is currently used in Brazil, mainly
in international multicenter trails, there is no study
assessing the reliability of this questionnaire in the
Brazilian Portuguese language. Therefore, the purpose of
this study was to evaluate the reproducibility of the FACT-L
and the FLSI for Brazilian lung cancer patients.
METHODS
A convenience sample comprising 30 patients with lung
cancer was recruited from the outpatient lung cancer clinic
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of the Sa˜o Paulo Hospital - Federal University of Sa˜o Paulo.
This study was approved by the Institutional Review Board
of our center, and a Term of Informed Consent was signed
by all patients.
The following inclusion criteria were used: histologically
proven lung cancer; 18 years of age or older; a minimum
score of 21 on the Mini Mental State Examination
(MMSE);10,11 out of chemotherapy/radiotherapy treatment;
and clinical stability during the study and at least 10 days
before the beginning of the evaluations. Clinical stability
was defined as the absence of change in cough, sputum, and
dyspnea, assessed by a structured form filled out during
outpatient follow-up, and no hospitalizations or modifica-
tions in the therapeutic regimen. An exclusion criterion was
the refusal to answer any questionnaire.
The sample size was based on previous reliability studies
of other quality of life questionnaires related to respiratory
diseases in Brazil.12–15
Clinical evaluation and physical examination were per-
formed by a team of physicians, based on a structured form.
All patients met the stability criteria. The drug regimen used
by the patients remained unchanged during the 15-day
interval between questionnaire applications.
In the first visit, the following independent variables were
collected: gender (male and female proportion), age (in
years), history of tobacco use (yes or no) and consumption
(pack–years), histologic subtypes (adenocarcinoma, squa-
mous cell, small cell lung cancer and others),16 staging
according to the 1997 TNM classification for non-small cell
lung cancer (NSCLC) patients (stratified from IA to IIIA and
from IIIB to IV),17 Karnofsky Performance Status (KPS),18
spirometry (forced expiratory volume in the first second
(FEV1) and forced vital capacity (FVC) percentage of
predicted and FEV1/FVC percentage),
19 MMSE, and
FACT-L and FLSI scores.9
The Portuguese version of the FACT-L and FLSI was
released for use by the FACIT group (the developer of the
questionnaire). The translation into Brazilian Portuguese,
back translation and review by an expert committee to
access the semantic, conceptual, idiomatic, cultural and
metabolic equivalences were previously done by that
group.20,21
The FACT-L, version 4, is a combination of the 27-item
FACT-General (FACT-G) and the 9-item Lung Cancer
Subscale (LCS).
A total FACT-G score is calculated by summing the
physical well-being (PWB), social/family well-being (SWB),
emotional well-being (EWB), and functional well-being
(FWB) subscale scores, with a score ranging from 0 to 108.
A total FACT-L score is obtained by summing the FACT-G
score with the LCS (two of the nine items are not scored).
The FACT-L score ranges from 0 to 136.6
The FACT-L Trial Outcome Index (FACT-L TOI) is, a
priori, an index that sums the PWB, FWB, and LCS into a 21-
item scale. Its score ranges from 0 to 84.6
The FLSI is a symptom index with six questions regarding
the five most frequent symptoms reported by lung cancer
patients, especially in the advanced stages: dyspnea, fatigue,
pain, weight loss, and coughing. Its score ranges from 0 to 24.
Higher scores generated by the FACT-L and FLSI
correspond to better quality of life.
The score on each aspect of the FACT-L and FLSI is
obtained according to the option chosen by the patient. The
available options were: ‘‘not at all’’, ‘‘a little bit’’, ‘‘some-
what’’, ‘‘quite a bit’’, or ‘‘very much’’. The higher the score
obtained by each patient in question, the greater the final
score of the subscale and the better the quality of life.
However, these scores have a non-linear behavior.
Patients answered the questionnaire after being read each
question, all by the same interviewer. The process took
place in a calm environment with no interruptions allowed.
The questionnaires were reviewed at the end of the
interview to avoid any missed questions. The response time
was timed in the two visits.
All doubts expressed by patients during the questionnaire
were documented. Patients were also asked not only about
what they felt in terms of question content, but also about
the length of the questionnaire.
The test–retest design was adopted for the reliability
study. The questionnaire was administered by the same
researcher twice with a 15-day interval.
The scores obtained on different scales and subscales of
FACT-G were compared with reference values established
by the FACIT group.22 For this comparison, we used the
minimal clinically significant difference, determined by the
same group.6
Statistical analysis
Variables were expressed as mean and standard devia-
tion. The intraclass correlation coefficient (ICC) and Kappa
reliability coefficient were calculated to assess the reliability
of the questionnaire and questions respectively. To compare
the two groups, we used the chi-square test for categorical
variables, t test for parametric continuous variables, and
Mann–Whitney test for nonparametric continuous variables.
For the correlations between spirometry and questionnaire
scores, the Spearman’s correlation coefficient was used.
Statistical analysis was performed with SPSSH software
version 13.0. All tests were two-tailed, and the level of
significance was 5%.
RESULTS
The main characteristics of the 30 patients who completed
the study are shown in Table 1. Some 63.3% of the patients
were over 60 years of age.
There was no statistically significant difference between
genders regarding age, KPS, spirometry, staging, and
histological type.
Among patients who never smoked, only one had a
history of passive smoking. There was a prevalence of
smoking habits in males (p= 0.04), with a higher tobacco
smoke load for men than for women, consuming a mean of
53.2 pack–years (SD = 31.6) and 29.6 pack–years (SD = 25.5)
respectively (p= 0.02).
Eight patients (26.7%) were diagnosed with chronic
obstructive pulmonary disease (COPD), according to the
GOLD guideline.23
The mean values for each scale of the FACT-L and FLSI are
illustrated in Table 2. The intraclass correlation coefficient
values for the different scales of the FACT-L and FLSI
showed excellent correlations (Table 2).
The kappa coefficient was used to test question reliability,
which was less than 0.4 on questions GP1, GP5 (PWB), GS3,
GS4, GS5 (SWB), GF1, GF2, GF3, GF5, GF6 (FWB), and LCL4
(LCS). The remaining questions had a moderate agreement.
As for the FLSI, the kappa coefficient was moderate on
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question B1. In the other questions, the kappa coefficient
was less than 0.4.
There was no correlation between spirometry and any of
the questionnaire scales.
The mean score of the FACT-G scales was similar to the
reference values for all scales that have these values
established.22 Table 3 shows the mean values for the scales
of FACT-G and FACT-L described in several studies of
reliability and cultural adaptation into other languages.
The time spent by patients in answering the questionnaire
was measured at both visits (Table 4). The response time on
the second application was significantly lower (p= 0.001).
DISCUSSION
The focus of this study was to analyze the reliability of the
FACT-L and the FLSI, a specific instrument for assessing the
quality of life of lung cancer patients in the Brazilian
population. It was observed that the Brazilian version shows
excellent reliability for this population.
The FACT-L is an instrument that has been widely used
in phase I, II, and III clinical trials. It has been translated and
adapted into several languages and cultures.2,3,7,22,24–27 A
feature of this instrument is the nonlinearity of the scores of
its scales, a factor that complicates the interpretation of
isolated study data. To facilitate the explanation of the
results, the authors of the general questionnaire (FACT-G)
have developed normative values from two reference
groups, one from normal adults and another from adults
with cancer in general.22 However, these normative values
are only for the general questionnaire (FACT-G) and its
scales. When comparing the results obtained in our study
with the reference values, we observe that the score was
similar in all scales and for the total value. A possible
explanation for the fact that our patients have quality of life
similar to patients with other cancer types is that, in the
study for the establishment of benchmarks, besides includ-
ing patients with various types of cancer, such as breast
cancer, colon and rectum cancer, and cancer of the head and
neck, they also included patients with lung cancer.
Furthermore, 76.7% of the sample comprised patients
treated and in remission from the underlying disease and,
Table 2 - Mean for the two visits (15-day interval) and
intraclass correlation coefficient (ICC) for FACT-L scales
and FLSI.
Scales 1st visit 2nd visit ICC
Physical well-being 22.9 22.7 0.90
Social/family well-being 19.5 18.6 0.78
Emotional well-being 18.4 19.0 0.92
Functional well-being 18.1 17.0 0.89
FACT-G 78.9 76.3 0.93
LCS 20.0 19.8 0.94
FACT-L 98.9 97.1 0.95
FACT-L TOI 61.0 59.6 0.96
FLSI 19.0 18.1 0.87
FACT-G, Functional Assessment of Cancer Therapy-General; LCS, Lung
Cancer Scale; FACT-L, Functional Assessment of Cancer Therapy-Lung;
FACT-L TOI, Functional Assessment of Cancer Therapy-Lung Trial Outcome
Index; FLSI, Functional Assessment of Cancer Therapy-Lung Symptom Index.
Table 1 - Subject characteristics of 30 lung cancer patients.
Variables
Age (years) mean¡SD 62.0¡10.4
Male n (%) 23 (73.7)
Smoking history
Former smokers n (%) 27 (90)
Never smokers n (%) 3 (10)
Pack–year mean¡DP 52.5¡33.4
Spirometry mean¡DP
FEV1 % prev 75.0¡19.1
FVC % prev 86.7¡13.1
FEV1 / FVC % 71.8¡12.2
Histological types n (%)
Adenocarcinoma 14 (46.7)




Staging status n (%)
I and II 14 (46.7)
III 13 (43.3)
IV 3 (10)
Mini Mental mean¡SD 27.9¡1.9
SD, standard deviation; FEV1, forced expiratory volume in the first second;
FVC, forced vital capacity; SCLC, small cell lung cancer; KPS, Karnofsky
Performance Status.
Table 3 - Mean values for the FACT-L scales in different reliability and validity trials with cancer patients.
Source PWB S/FWB EWB FWB FACT-G LCS FACT-L FACT-L TOI
Current study 21.7 19.8 18.4 16.6 76.5 19.3 95.8 57.6
Brucker et al 2005 21.3 22.1 18.7 18.9 80.9 – – –
Browning et al 2009 16.5 20.4 14.2 13.8 – 16.2 81.1 46.3
Wan et al 2007 18.3 18.2 16.3 12.2 65.9 16.7 82.9 47.2
Saitoh et al 2007 – – – – – 17.8 – –
Yoo et al 2006 20.7 23.2 15.5 17.4 84.1 20.5 – 59.0
Cella et al 2003 20.2 22.7 16.4 16.1 73.7 18.9 94.6 33.4
Dapueto et al 2003 15.7 18.6 13.5 16.0 63.7 – – –
Cella et al 1995 20.7 23.2 15.5 17.4 84.1 20.3 – 59.0
PWB, physical well-being; S/FWB, social/family well-being; EWB, emotional well-being; FWB, functional well-being; FACT-G, Functional Assessment of
Cancer Therapy-General; LCS, Lung Cancer Scale; FACT-L, Functional Assessment of Cancer Therapy-Lung; FACT-L TOI, Functional Assessment of Cancer
Therapy-Lung Trial Outcome Index.
Table 4 - Response time of the FACT-L and FLSI and p
value of the comparison between the two visits
(Student’s t test).
Mean Median SD Range p
1st FACT-L + FLSI 9.6 8 3.8 5–20 0.001
2nd FACT-L + FLSI 9.0 9 2.9 4–15
FACT-L, Functional Assessment of Cancer Therapy-Lung; FLSI, Functional
Assessment of Cancer Therapy-Lung Symptom Index.
CLINICS 2010;65(12):1247-1251
1249
therefore, with better quality of life. When our FACT-L
results are compared with those from other studies using
the same questionnaire, we find that there is great
variability between countries and different cul-
tures,2,3,7,22,24–27 which may be due to differing perceptions
of the questions according to each culture and also
differences in patient characteristics, such as staging, age,
socioeconomic status, among others.
The FLSI is an index designed to identify the presence of
the major symptoms related to lung cancer, including
dyspnea, pain, fatigue, cough, and weight loss.28 These
symptoms can negatively influence quality of life. In this
study, in addition to the medical evaluation, FLSI was also
used to assess the patient’s clinical stability.
The reliability for all scores of the FACT-L showed ICC
values greater than 0.75, ranging from 0.78 (SWB) to 0.96
(FACT-L TOI). These values show excellent reliability and
are similar to those found in other studies. In the validation
study of the Korean version of the FACT-L,25 the ICC
ranged from 0.52 to 0.84. The Chinese version3 varied from
0.76 to 0.82. In the reliability study of the original version,
the ICC ranged from 0.56 (SWB) to 0.89 (FACT-L TOI).7 The
FLSI also showed high reliability, which confirms the
stability of the sample. Most of the FACT-L questions
showed adequate reliability, analyzed by the kappa coeffi-
cient.
In this study, the reliability analyses were conducted with
a convenience sample similar to other studies evaluating the
reliability and cultural adaptation of other questionnaires to
the Portuguese language.12–15
In our sample, males predominated, in agreement with
the worldwide prevalence of lung cancer.1 The mean age
was 61.3 years, which is consistent with most studies that
include patients with lung cancer.1,5 Regarding histological
type, adenocarcinoma was the most prevalent, consistent
with several epidemiological studies in developed coun-
tries.1 Unfortunately, regarding staging, there was a
predominance of stage III and IV, stages with less chance
of survival after treatment.29 The mean FEV1 (% predicted)
and FEV1/FVC ratio in our study were similar to the results
reported by Young et al., who observed a FEV1 (%
predicted) mean of 73% and FEV1/FVC mean of 64% in
smokers with lung cancer.30 In our study, there was no
correlation between the questionnaire and the analyzed
lung function parameters, consistent with other studies that
found no significant correlation when investigating the
effects of altered pulmonary function on the quality of life of
cancer patients.31,32
The process of translating the FACT-L questionnaire and
FLSI into the Portuguese language (Brazil) was performed
by the FACIT group. Only a few doubts were reported by
the patients, which warrants its use in the current form.
Few patients had difficulty in interpreting the word
‘‘muitı´ssimo’’; however, many of the patients interviewed
understood the meaning of the term not because it is a
familiar word, but because they realized that it was a scale
with a progressive score in which the numerical value
assigned to the word ‘‘muitı´ssimo’’ yielded the highest
score. The suggested changes were sent to the FACIT group.
Alterations to this tool were proposed only for question
Q1 ‘‘Independentemente do seu nı´vel a(c)tual de a(c)tivi-
dade sexual, favor de responder a` pergunta a seguir. Se
preferir na˜o responder, assinale o quadrı´culo % e passe
para a pro´xima sec¸a˜o’’. Despite not raising doubts, the
words ‘‘atual’’ and ‘‘atividade’’ do not require the letter
‘‘(c)’’, and there is no need to use the preposition ‘‘de’’ after
the word ‘‘favor’’, both grammatical constructions used in
the Portuguese language in Portugal.
We conclude that the Brazilian version of the FACT-L
questionnaire and FLSI is reproducible, fast, and of simple
application, and that they are capable of measuring the
quality of life in lung cancer patients in Brazil.
REFERENCES
1. Landi MT, Consonni D, Rotunno M, Bergen AW, Goldstein AM, Lubin
JH, et al. Environment and Genetics in Lung cancer Etiology (EAGLE)
study: an integrative population-based case-control study of lung cancer.
BMC Public Health. 2008;8:203, doi: 10.1186/1471-2458-8-203.
2. Browning KK, Ferketich AK, Otterson GA, Reynolds NR, Wewers ME. A
psychometric analysis of quality of life tools in lung cancer patients who
smoke. Lung Cancer. 2009;66:134–9, doi: 10.1016/j.lungcan.2008.12.018.
3. Wan C, Zhang C, Cai L, Tu X, Feng C, Luo J, et al. Psychometric
properties of the Chinese version of the FACT-L for measuring quality of
life in patients with lung cancer. Lung Cancer. 2007;56: 415–21, doi: 10.
1016/j.lungcan.2007.01.004.
4. Brasil. Ministe´rio da Sau´de. Instituto Nacional de Caˆncer I. Estimativa
2010: Incideˆncia de Caˆncer no Brasil. Rio de Janeiro: INCA; 2009.
5. Franceschini J, Santos AA, El Mouallem I, Jamnik S, Uehara C, Fernandes
AL, et al. [Assessment of the quality of life of patients with lung cancer
using the Medical Outcomes Study 36-item Short-Form Health Survey].
J Bras Pneumol. 2008;34:387–93, doi: 10.1590/S1806-37132008000600009.
6. Butt Z, Webster K, Eisenstein AR, Beaumont J, Eton D, Masters GA, et al.
Quality of life in lung cancer: the validity and cross-cultural applicability
of the Functional Assessment of Cancer Therapy-Lung scale. Hematol
Oncol Clin North Am. 2005;19:389–420, viii, doi: 10.1016/j.hoc.2005.02.
009.
7. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P.
Reliability and validity of the Functional Assessment of Cancer Therapy-
Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12:199–220,
doi: 10.1016/0169-5002(95)00450-F.
8. Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung
cancer: a review of literature from 1970 to 1995. Chest. 1998;113:467–81,
doi: 10.1378/chest.113.2.467.
9. Webster K, Cella D, Yost K. The Functional Assessment of Chronic
Illness Therapy (FACIT) measurement system: properties, applications,
and interpretation. Health Qual Life Outcomes. 2003; 1:79, doi: 10.1186/
1477-7525-1-79.
10. Folstein MF, Folstein SE, McHugh PR. ‘‘Mini-mental state’’. A practical
method for grading the cognitive state of patients for the clinician.
J Psychiatr Res. 1975;12:189–98, doi: 10.1016/0022-3956(75)90026-6.
11. Almeida OP. [Mini mental state examination and the diagnosis of
dementia in Brazil]. Arq Neuropsiquiatr. 1998;56:605–12.
12. Camelier A, Rosa FW, Salim C, Nascimento OA, Cardoso F, Jardim JR.
Using the Saint George’s Respiratory Questionnaire to evaluate quality
of life in patients with chronic obstructive pulmonary disease: validating
a new version for use in Brazil. J Bras Pneumol. 2006;32:114–22, doi: 10.
1590/S1806-37132006000200006.
13. Carpes MF, Mayer AF, Simon KM, Jardim JR, Garrod R. The Brazilian
Portuguese version of the London Chest Activity of Daily Living scale
for use in patients with chronic obstructive pulmonary disease. J Bras
Pneumol. 2008;34:143–51, doi: 10.1590/S1806-37132008000300004.
14. Sousa T, Jardim J, Jones P. Validac¸a˜o do Questiona´rio do Hospital Saint
George na Doenc¸a Respirato´ria (SGRQ) em pacientes portadores de
doenc¸a pulmonar obstrutiva croˆnica no Brasil. J Pneumol. 2000;26:119–28.
15. Kovelis D, Segretti NO, Probst VS, Lareau SC, Brunetto AF, Pitta F.
Validation of the Modified Pulmonary Functional Status and Dyspnea
Questionnaire and the Medical Research Council scale for use in
Brazilian patients with chronic obstructive pulmonary disease. J Bras
Pneumol. 2008;34:1008–18.
16. Uehara C, Santoro I, Ferreira R. Caˆncer de pulma˜o: diagno´stico e
estadiamento. In: Nery L, Fernandes A, Perfeito J, eds. Pneumologia.
Barueri: Manole; 2006. p. 495–509.
17. Mountain CF. Revisions in the International System for Staging Lung
Cancer. Chest. 1997;111:1710–17, doi: 10.1378/chest.111.6.1710.
18. Karnofsky DA, Golbey RB, Pool JL. Preliminary studies on the natural
history of lung cancer. Radiology. 1957;69:477–88.
19. Pereira C. Espirometria. J Pneumol. 2002;28(Suppl. 3):S1–S82.
20. Arnold BJ, Eremenco E, Chang C-H, Odom L, Ribaudo JM, Cella D.
Development of a single Portuguese language version of the Functional
Assessment of Cancer Therapy - General (FACT-G) Scale. Qual Life Res.
2000;9:316.
21. Arnold BJ, Eremenco S, Chang CH, Cella D, Riberiro JLP, Doro MP et al.
How much is ‘‘very much’’? Developing a rating scale for Portuguese
speaking countries. Qual Life Res. 2001; 10:264.
CLINICS 2010;65(12):1247-1251
1250
22. Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and
cancer patient norms for the Functional Assessment of Cancer Therapy-
General (FACT-G). Eval Health Prof. 2005;28:192–211, doi: 10.1177/
0163278705275341.
23. Rodriguez-Roisin R, Anzueto A, Bourbeau J, Calverley P, DeGuia T,
Fukuchi Y, et al. GOLD – Global Initiative for Chronic Obstructive
Pulmonary Disease – Pocket Guide to COPD Diagnoses, Management
and Prevention. A Guide for Healthcare Professionals. Medical
Communications Resources, Inc.; 2009.
24. Saitoh E, Yokomizo Y, Chang C-H, Eremenco S, Kaneko H, Kobayashi K.
Cross-cultural validation of the Japanese version of the lung cancer
subscale on the Functional Assessment of Cancer Therapy-Lung.
J Nippon Med Sch. 2007;74:402–8, doi: 10.1272/jnms.74.402.
25. Yoo H, Suh C, Kim S, Eremenco S, Kim H, Kim S. Korean translation and
validation of the Functional Assessment of Cancer Therapy-Lung
(FACT-L) version 4. Qual Life Res. 2006;15:161–6, doi: 10.1007/s11136-
005-8752-x.
26. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring
the side effects of taxane therapy in oncology: the Functional Assessment
of Cancer Therapy-Taxane (FACT-taxane). Cancer. 2003;98:822–31, doi:
10.1002/cncr.11578.
27. Dapueto JJ, Francolino C, Servente L, Chang CH, Gotta I, Levin R, et al.
Evaluation of the Functional Assessment of Cancer Therapy-General
(FACT-G) Spanish version 4 in South America: classic psychometric and
item response theory analyses. Health Qual Life Outcomes. 2003;1:32,
doi: 10.1186/1477-7525-1-32.
28. Eton DT, Cella D, Yount SE, Davis KM. Validation of the Functional
Assessment of Cancer Therapy-Lung Symptom Index-12 (FLSI-12). Lung
Cancer. 2007;57:339–47, doi: 10.1016/j.lungcan.2007.03.021.
29. Hammerschmidt S, Wirtz H. Lung cancer: current diagnosis and
treatment. Dtsch Arztebl Int. 2009;106:809–18; quiz 819–20.
30. Young RP, Hopkins RJ, Hay BA, Epton MJ, Mills GD, Black PN, et al. Lung
cancer susceptibility model based on age, family history and genetic
variants. PLoS One. 2009;4:e5302, doi: 10.1371/journal.pone.0005302.
31. Ozturk A, Sarihan S, Ercan I, Karadag M. Evaluating quality of life and
pulmonary function of long-term survivors of non-small cell lung cancer
treated with radical or postoperative radiotherapy. Am J Clin Oncol.
2009;32:65–72, doi: 10.1097/COC.0b013e31817e6ec2.
32. Sarna L, Evangelista L, Tashkin D, Padilla G, Holmes C, Brecht ML, et al.
Impact of respiratory symptoms and pulmonary function on quality of
life of long-term survivors of non-small cell lung cancer. Chest.
2004;125:439–45, doi: 10.1378/chest.125.2.439.
CLINICS 2010;65(12):1247-1251
1251
